Renal arteries denervation: from the treatment of resistant hypertension to the treatment of atrial fibrillation

Francesco Versaci, Sebastiano Sciarretta, Massimiliano Scappaticci, Riccardo Di Pietro, Simone Calcagno, Armando Del Prete, Carlo Gaspardone, Giuseppe Biondi Zoccai

Research output: Contribution to journalArticlepeer-review


Renal denervation (RDN) is a therapeutic strategy for patients with uncontrolled arterial hypertension characterized by considerable fluctuations during its progression. After initial strong enthusiasm, the procedure came to an abrupt halt following the publication of the Symplicity HTN-3 study results. The results of recently published studies highlight the reduction in blood pressure values after RDN and justify the inclusion in the Guidelines of new recommendations for the use of RDN in clinical practice, in selected patients. Additionally, RDN findings are summarized in view of other potential indications such as atrial fibrillation. Six prospective, randomized studies are presented that evaluated RDN as an adjunct therapy to pulmonary vein isolation for the treatment of atrial fibrillation. In five studies, patients had uncontrolled hypertension despite therapy with three antihypertensive drugs. The analysis of these studies showed that RDN reduced the recurrence of atrial fibrillation (AF) by 57% compared to patients with pulmonary vein isolation (PVI) only. Modulation of the autonomic nervous system by RDN has been shown not only to reduce blood pressure but also to have an antiarrhythmic effect in symptomatic AF patients when the strategy is combined with PVI, thus opening up new therapeutic scenarios.

Original languageEnglish
Pages (from-to)E177-E183
JournalEur. Heart J. Suppl.
Issue numberSuppl E
Publication statusPublished - Oct 2021


Dive into the research topics of 'Renal arteries denervation: from the treatment of resistant hypertension to the treatment of atrial fibrillation'. Together they form a unique fingerprint.

Cite this